Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

In this case study, researchers reported that a patient with plaque alopecia areata experienced complete and sustained hair regrowth after treatment with 5-Fluorouracil and Bleomycin via microinfusion of medicines, despite initial cutaneous atrophy caused by intralesional corticosteroid therapy.

This study found that adalimumab treatment led to regression of lesions in two patients with hidradenitis suppurativa after 16 weeks of therapy.

This study identifies a mechanism where dsRNA activates TLR3 to induce RA production, promoting hair follicle regeneration in mice and suggesting a potential role in human tissue regeneration.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

In this case report, a patient with ankylosing spondylitis and alopecia areata who used a combination of baricitinib and golimumab experienced hair regrowth without adverse effects, but the efficacy of this treatment combination remains unestablished according to the researchers.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

RCS-01 is safe and may help rejuvenate aging skin.

This study found that MDSC exosomes promoted partial hair regrowth and modulated immune responses in mice with alopecia areata, suggesting potential as a treatment for autoimmune diseases.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

This study concluded that the combination of all-trans-retinoic acid and tocopherol-α is not recommended for treating del(5q) myelodysplastic syndromes due to low efficacy and high incidence of adverse effects.

This study reviewed 18 studies on the effects of ustekinumab and vedolizumab on alopecia in ulcerative colitis patients, finding varied outcomes ranging from significant hair regrowth to increased hair loss, with 65.5% experiencing regrowth and potential therapy benefits needing further exploration in larger trials.

The FDA approved a new Pfizer drug for hair loss in teens.

A girl with Crohn's disease developed hair loss from her medication, which improved with treatment but later returned.

In a post-hoc analysis of six trials, this study observed that both adult and pediatric patients with moderate-to-severe palmoplantar psoriasis treated with ixekizumab experienced rapid and complete clearance of lesions, sustained for up to 5 years in adults and 2 years in children.

Martin-Perez et al. show that rapamycin's beneficial effects in a mouse model of Leigh syndrome are linked to the downregulation of protein kinase C.

This pilot study suggests that a new preparation of platelet-rich plasma gel may improve symptoms and tissue regeneration in patients with en coup de sabre scleroderma, though further trials are needed to clarify its role.

This study observed that topically applied RTA 408 reduced the severity of radiation-induced dermatitis in mice, with the highest dose significantly reducing and alleviating skin damage and associated inflammation.

This study found that hair follicle-derived mesenchymal stem cells can alleviate pyroptosis and improve ulcerative colitis symptoms in mice, suggesting potential new treatments for the condition.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This review discusses previously reported cases of drug-associated hidradenitis suppurativa linked to various immunomodulating medications but reports no new clinical results.

This case report describes a young girl with a rare association of anti-SRP positive necrotizing autoimmune myopathy and systemic lupus erythematosus, who responded well to corticosteroid treatment.

This communication reports previously unreported side effects, severe bullous dermatosis and onycholysis, in three patients undergoing high-dose methotrexate and leucovorin calcium therapy, impacting their chemotherapy schedules.